Abstract
α-phellandrene antiedematogenic effect (α-Phel) was evaluated in carrageenan, histamine, prostaglandin and substance P induced paw edema and croton oil, TPA and arachidonic acid induced ear edemain mice. Experimental protocols were approved by Ethical Committee for Animal Experimentation (CEEA/UFPI, Protocol Nº 010/2011). α-Phel (100 and 200 mg.kg-1, p.o.) reduced carrageenan and prostaglandina (40.97 % and 61.41 %, respectively) induced paw edema, in doses 50, 100 e 200 mg.kg-1, p.o. reduced histamina induced paw edema formation (31.27 %; 45.14 % e 47.29 %, respectively); on substance P induced paw edema the inhibition occurred when the animal were treated with 200 mg.kg-1 of α-Phel, p.o. (44.05 %).When administered topically, α-Phel (0.2 e 0.4 mg/ear) reduced croton oil (57.34 % e 62.42 %, respectively), TPA (48.29 % e 62.10 %, respectively)and arachidonic acid(0.4 mg/ear) induced ear edema (29.55 %).α-Phelpresents antiedematogenic activity in acute inflammation models.
Keywords: Monoterpene, α-Phellandrene, anti-inflammatory activity, edema.
Graphical Abstract
Current Bioactive Compounds
Title:Antiedematogenic Effect of α-Phellandrene in Animal Models
Volume: 12 Issue: 2
Author(s): Hálmisson D.S. Siqueira, Benedito P.S. Neto, Damião P. Sousa, Bruno S. Gomes, Francisco V.M. Cunha and Francisco A. Oliveira
Affiliation:
Keywords: Monoterpene, α-Phellandrene, anti-inflammatory activity, edema.
Abstract: α-phellandrene antiedematogenic effect (α-Phel) was evaluated in carrageenan, histamine, prostaglandin and substance P induced paw edema and croton oil, TPA and arachidonic acid induced ear edemain mice. Experimental protocols were approved by Ethical Committee for Animal Experimentation (CEEA/UFPI, Protocol Nº 010/2011). α-Phel (100 and 200 mg.kg-1, p.o.) reduced carrageenan and prostaglandina (40.97 % and 61.41 %, respectively) induced paw edema, in doses 50, 100 e 200 mg.kg-1, p.o. reduced histamina induced paw edema formation (31.27 %; 45.14 % e 47.29 %, respectively); on substance P induced paw edema the inhibition occurred when the animal were treated with 200 mg.kg-1 of α-Phel, p.o. (44.05 %).When administered topically, α-Phel (0.2 e 0.4 mg/ear) reduced croton oil (57.34 % e 62.42 %, respectively), TPA (48.29 % e 62.10 %, respectively)and arachidonic acid(0.4 mg/ear) induced ear edema (29.55 %).α-Phelpresents antiedematogenic activity in acute inflammation models.
Export Options
About this article
Cite this article as:
D.S. Siqueira Hálmisson, P.S. Neto Benedito, P. Sousa Damião, S. Gomes Bruno, V.M. Cunha Francisco and A. Oliveira Francisco, Antiedematogenic Effect of α-Phellandrene in Animal Models, Current Bioactive Compounds 2016; 12 (2) . https://dx.doi.org/10.2174/1573407212666160210231052
DOI https://dx.doi.org/10.2174/1573407212666160210231052 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Hybrid Compound 4-[(E)-2-phenylethenesulfonamido]-N-hydroxybutanamide with Antimetastatic and Cytotoxic Action: Synthesis and Anticancer Screening
Anti-Cancer Agents in Medicinal Chemistry Immune System Modulation by Thyroid Axis Includes Direct Genomic and Nongenomic Actions of Thyroid Hormones on Immune Cells
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Impact of Diabetes on Vasculature: Focus on Nervous System
Current Diabetes Reviews Central Blood Pressure in Chronic Kidney Disease: Latest Evidence and Clinical Relevance
Current Hypertension Reviews Editorial (Thematic Issue: Clinical Advances in Immuno-oncology – Progress Towards Selective Cure)
Current Molecular Pharmacology Phenolic Acids Exert Anticholinesterase and Cognition-Improving Effects
Current Alzheimer Research Alcohol Consumption and Risk of Uterine Fibroids
Current Molecular Medicine Inhaled Insulin and the Lung
Current Medicinal Chemistry Cyclic-3-hydroxymelatonin (C3HOM), A Potent Antioxidant, Scavenges Free Radicals and Suppresses Oxidative Reactions
Current Medicinal Chemistry Pharmacogenetics, Target Molecules, and Biological Anti-Rheumatic Drugs in Autoimmune/Chronic Inflammatory Rheumatic Diseases
Current Pharmacogenomics Drug-Induced Aseptic Meningitis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Reversion of Multidrug Resistance in Tumor By Biocompatible Nanomaterials
Mini-Reviews in Medicinal Chemistry Role of C-Type Lectins in Mycobacterial Infections
Current Drug Targets The Two Faces of Protein Palmitoylation in Islet β-Cell Function: Potential Implications in the Pathophysiology of Islet Metabolic Dysregulation and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Licofelone-A Novel Analgesic and Anti-Inflammatory Agent
Current Topics in Medicinal Chemistry Vascular Homing Peptides with Cell-Penetrating Properties
Current Pharmaceutical Design Encouraging microRNA-based Therapeutic Strategies for Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Post-translational Modifications of bZIP Transcription Factors in Abscisic Acid Signaling and Drought Responses
Current Genomics The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients
Recent Patents on Inflammation & Allergy Drug Discovery Chemical Constituents of Plants from the Genus Forsythia
Mini-Reviews in Organic Chemistry